BioSpace News Archive

Leading US integrated site company, Velocity Clinical Research, today announces the acquisition of Downtown Women’s Health Care (DWHC), CO and Riverside Clinical Research, FL to its North American site portfolio, bringing the total to 16.

FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, and Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, announced today that Sana has been granted a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development of commercial cell therapies.

ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the fourth quarter of 2020 on Thursday, March 25, 2021 after the close of trading on the U.S. financial markets.

Genetron Health to Participate at Credit Suisse Asian Investment Conference on Mar. 26 th , 2021

IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the six months ended January 31, 2021.

Organon Proposed Board of Directors To Have More Women Than Any S&P 500 Healthcare Company Investor Day Planned for May 3 Ahead of Spinoff in Late Second Quarter 2021

A multi-disciplinary team of physicians and clinical professionals meticulously planned the hospital’s first surgery to provide a patient with a new heart and a new liver

Pharma-Bio Serv, Inc. (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2021 were approximately $4,488,000

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, PhaseBio expects to grant the underwriters a 30-day option to purchase additional shares of its common stock

Substantial progress in priority development pathway in head and neck cancer with clinical registration plan announced, Fast Track designation granted by US Food and Drug Administration, and new data from phase I dose expansion showing 83% objective response rate in primary lesion.